Enclomiphene vs Pitavastatin
Well Studied vs FDA Approved
avoid Mechanism-based · 64% Both Enclomiphene and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Enclomiphene Pitavastatin
Weight 405.96 Da 421.46 Da
Half-life ~10 hours ~12 hours
Type Trans-isomer of clomifene (selective estrogen receptor modulator) Synthetic statin (C25H24FNO4)
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Pitavastatin
01 Minimal CYP450 metabolism — does not interact with CYP3A4, making it ideal for users taking multiple compounds
02 Lowest risk of new-onset diabetes among all statins, supported by the LIVES study and J-PREDICT trial data
03 LDL reductions of 38-45% at standard doses (2-4 mg/day)
04 More robust HDL-raising effect (5-15%) compared to other statins in the class
05 12-hour half-life supports convenient once-daily dosing
06 Favorable safety profile with low incidence of muscle-related side effects
07 Compatible with CYP3A4 inhibitors and inducers that would alter levels of other statins
08 Effective at counteracting AAS-induced lipid disturbances without adding to drug interaction burden
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Pitavastatin
Myalgia and muscle discomfort (approximately 3-5% of users) — generally mild and less frequent than with lipophilic statins
Headache
Minimal liver enzyme elevation — typically transient and clinically insignificant
Back pain
Constipation or diarrhea
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to pitavastatin or any excipients
Pregnancy and breastfeeding (Category X — statins are teratogenic)
Concomitant use with cyclosporine (significantly increases pitavastatin levels via OATP1B1 inhibition)
Concomitant use with lopinavir/ritonavir or atazanavir/ritonavir combinations
Research Evidence
Enclomiphene Pitavastatin
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest — 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.